Trial: Erbitux-FOLFOX Therapy Improves PFS, OS in RAS Wild-Type Colorectal Cancer

Alessio Pigazzi, expert in robot-assisted techniques, selected as new colorectal surgery leader at Cedars-Sinai

Alessio Pigazzi was chosen to lead the newly created faculty division of colorectal surgery in the Jim and Eleanor Randall Department of Surgery at Cedars-Sinai.

October 03, 2025

Vol.51 No.36

In Brief

The University of Cincinnati researchers win NCI grant to study combination colorectal cancer treatment

The University of Cincinnati Cancer Center’s Joan Garrett has received a two-year, $162,000 NCI grant to study a new combination approach to treat KRAS-mutated colorectal cancers.

October 03, 2025

Vol.51 No.36

Clinical Roundup

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity.

September 26, 2025

Vol.51 No.35

Clinical Roundup

ALOX15 loss, common in CRC, impairs the cancer-preventative effects of fish oil, mouse study shows

About 19 million American adults consume dietary fish oil supplements. These supplements, which primarily consist of the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid, are widely used as a remedy for chronic diseases. However, the effects of EPA and DHA supplementation on cancer risk have been inconsistent.

September 26, 2025

Vol.51 No.35

Clinical Roundup

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

ELI-002 2P, an off-the-shelf cancer vaccine, can trigger powerful and lasting immune responses, and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations, according to a study published in Nature Medicine.

September 05, 2025

Vol.51 No.32

Drugs & Targets

ColoAlert colorectal screening test receives approval in Switzerland

ColoAlert, a non-invasive colorectal cancer screening test, has been officially registered and approved for distribution by Swissmedic, the Swiss regulatory and supervisory authority for medicinal products and medical devices. The test is designed to detect CRC tumor DNA and other biomarkers with high sensitivity in stool samples.

September 05, 2025

Vol.51 No.32

Trial: Erbitux-FOLFOX Therapy Improves PFS, OS in RAS Wild-Type Colorectal Cancer

YOU MAY BE INTERESTED IN

Alessio Pigazzi, expert in robot-assisted techniques, selected as new colorectal surgery leader at Cedars-Sinai

The University of Cincinnati researchers win NCI grant to study combination colorectal cancer treatment

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

ALOX15 loss, common in CRC, impairs the cancer-preventative effects of fish oil, mouse study shows

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

ColoAlert colorectal screening test receives approval in Switzerland

Renew today!

Subscriber content

Never miss an issue!

Login